Novartis Cash And Short Term Investments from 2010 to 2024

NVS Stock  USD 98.35  1.07  1.10%   
Novartis Cash And Short Term Investments yearly trend continues to be comparatively stable with very little volatility. Cash And Short Term Investments will likely drop to about 13.1 B in 2024. Cash And Short Term Investments is the sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash. View All Fundamentals
 
Cash And Short Term Investments  
First Reported
2000-06-30
Previous Quarter
12.7 B
Current Value
14 B
Quarterly Volatility
4.2 B
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Novartis financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Novartis main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.3 B, Interest Expense of 550.6 M or Selling General Administrative of 15 B, as well as many exotic indicators such as Price To Sales Ratio of 3.66, Dividend Yield of 0.0254 or PTB Ratio of 3.07. Novartis financial statements analysis is a perfect complement when working with Novartis Valuation or Volatility modules.
  
This module can also supplement Novartis' financial leverage analysis and stock options assessment as well as various Novartis Technical models . Check out the analysis of Novartis Correlation against competitors.

Latest Novartis' Cash And Short Term Investments Growth Pattern

Below is the plot of the Cash And Short Term Investments of Novartis AG ADR over the last few years. Short Term Investments is an account in the current assets section of Novartis AG ADR balance sheet. This account contains Novartis investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Novartis AG ADR fairly quickly. It is the sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash. Novartis' Cash And Short Term Investments historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Novartis' overall financial position and show how it may be relating to other accounts over time.
Cash And Short Term Investments10 Years Trend
Slightly volatile
   Cash And Short Term Investments   
       Timeline  

Novartis Cash And Short Term Investments Regression Statistics

Arithmetic Mean12,129,883,894
Geometric Mean11,011,426,825
Coefficient Of Variation48.39
Mean Deviation4,179,079,277
Median11,446,000,000
Standard Deviation5,869,141,970
Sample Variance34446827.5T
Range23.3B
R-Value0.60
Mean Square Error23705698.7T
R-Squared0.36
Significance0.02
Slope788,492,008
Total Sum of Squares482255584.5T

Novartis Cash And Short Term Investments History

202413.1 B
202314 B
202218.9 B
202128.3 B
202011.6 B
201911.4 B
201816 B

About Novartis Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Novartis income statement, its balance sheet, and the statement of cash flows. Novartis investors use historical funamental indicators, such as Novartis's Cash And Short Term Investments, to determine how well the company is positioned to perform in the future. Although Novartis investors may use each financial statement separately, they are all related. The changes in Novartis's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Novartis's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Novartis Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Novartis. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cash And Short Term Investments14 B13.1 B

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Novartis AG ADR is a strong investment it is important to analyze Novartis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Novartis' future performance. For an informed investment choice regarding Novartis Stock, refer to the following important reports:
Check out the analysis of Novartis Correlation against competitors.
You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Complementary Tools for Novartis Stock analysis

When running Novartis' price analysis, check to measure Novartis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novartis is operating at the current time. Most of Novartis' value examination focuses on studying past and present price action to predict the probability of Novartis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novartis' price. Additionally, you may evaluate how the addition of Novartis to your portfolios can decrease your overall portfolio volatility.
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Is Novartis' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Novartis. If investors know Novartis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Novartis listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.215
Dividend Share
3.919
Earnings Share
4.1
Revenue Per Share
23.168
Quarterly Revenue Growth
0.097
The market value of Novartis AG ADR is measured differently than its book value, which is the value of Novartis that is recorded on the company's balance sheet. Investors also form their own opinion of Novartis' value that differs from its market value or its book value, called intrinsic value, which is Novartis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Novartis' market value can be influenced by many factors that don't directly affect Novartis' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Novartis' value and its price as these two are different measures arrived at by different means. Investors typically determine if Novartis is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Novartis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.